Suggestions for BC patients receiving TT include close cooperation between cardiologists and oncologists; inclusion of a cardiologist as a Breast Unit team member; not using NT-proBNP, CK-MB, or myoglobin as standard TIC predictive markers; also including patients without cardiac risk factors in close cardiac monitoring; in patients with TIC, a close follow-up of cardiac toxicity is recommended as TT can be resumed in the majority of patients. This evidence concerns the gene MB and breast cancer.